Scientific publications

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective

Fotopoulou C (1), Sehouli J (1), Aletti G (1), Harter P (1), Mahner S (1), Querleu D (1), Chiva L (1), Gabra H (1), Colombo N (1), du Bois A (1). (1) Christina Fotopoulou, Imperial College London, London, United Kingdom; Jalid Sehouli, Charité Medical University of Berlin, Berlin, Germany; Giovanni Aletti, European Institute of Oncology, Milan, Italy; Philipp Harter, Kliniken Essen Mitte, Essen, Germany; Sven Mahner, Ludwig-Maximilians-University, Munich, Germany; Denis Querleu, Institut Bergonié, Bordeaux, France; Luis Chiva, Clínica Universidad de Navarra, Navarra, Spain; Hani Gabra, Imperial College London, London, United Kingdom; Nicoletta Colombo, European Institute of Oncology, Milan, Italy; and Andreas du Bois, Kliniken Essen Mitte, Essen, Germany.

Magazine: Journal of Clinical Oncology

Date: Jan 9, 2017

Gynaecology and Obstetrics

The timing of debulking surgery in advanced ovarian cancer (AOC) has been the focus of debate and controversy in the international community for almost a decade.

Although supporters of primary debulking surgery (PDS) advocate significantly better overall survival (OS) and progression-free survival rates, with even a significantly favorable impact on the patterns of relapse, 4 opponents argue higher morbidity in a highly heterogeneous and often fatal disease.

For more than two decades, we have known that each 10% increase in maximal cytoreduction is associated with a 5.5% increase in median survival, even after controlling for all other known patient- and tumor-specific variables.

However, because of the unusual tumor biology and clinical behavior of AOC, with a typical diffuse peritoneal dissemination, in the majority of cases complete debulking is associated with multivisceral resections that require extensive surgical expertise, training, and infrastructural support to not lead to an exponential increase in morbidity.

CITAÇÃO DO ARTIGO  J Clin Oncol. 2017 Jan 9:JCO2016710723

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra